Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sham therapy Clear all
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acupressure for Fatigue in Systemic Lupus Erythematosus

NCT03200548
View directory record Official record
Conditions
Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep
Interventions
Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care, Sham acupressure plus usual care
Behavioral
Lead sponsor
Suzanna Zick
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
View directory record Official record
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2010 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Smoking, Sex Hormones, and Pregnancy

NCT01811225
View directory record Official record
Conditions
Nicotine Dependence, Contraception
Interventions
Low-dose Progesterone, High-dose Progesterone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

NCT03205917
View directory record Official record
Conditions
HIV Infections
Interventions
PGDM1400/Placebo (3mg/kg IV), PGDM1400/Placebo (10mg/kg IV), PGDM1400/Placebo (30mg/kg IV), PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV), PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV), PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV), PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV), PGDM1400 + PGT121 (MTD IV)
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
View directory record Official record
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Inorganic Nitrate Supplement on Blood Pressure

NCT03909789
View directory record Official record
Conditions
Blood Pressure, Endothelial Dysfunction
Interventions
Plant based bioequivalent Nitrate supplementation, Placebo
Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 21, 2026, 6:55 PM EDT
Terminated Phase 2 Interventional

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

NCT00698789
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB019602, Placebo, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2012 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

NCT01265550
View directory record Official record
Conditions
GERD
Interventions
Nissen fundoplication, baclofen, Desipramine
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

NCT01375491
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

NCT00502710
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO4876904
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Hot Springs, Arkansas • Concord, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

NCT04389723
View directory record Official record
Conditions
Healthy, Cognitive Function
Interventions
Qualia Mind, Placebo
Dietary Supplement
Lead sponsor
Neurohacker Collective
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

NCT03600480
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 4 Interventional

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 6:55 PM EDT
Recruiting Phase 3 Interventional

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

NCT07456696
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
TSND-201, Placebo
Drug
Lead sponsor
Transcend Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 21, 2026, 6:55 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 21, 2026, 6:55 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Bovine Colostrum to Prevent Absorption of Gluten

NCT05555446
View directory record Official record
Conditions
Celiac Disease, Gluten Sensitivity, Non-celiac Gluten Sensitivity
Interventions
Bovine colostrum, Placebo
Dietary Supplement
Lead sponsor
Milky Way Life Sciences LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

NCT02633488
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Sensitivity
Interventions
Placebos, metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

A Study of IDN-6556 in Subjects With Liver Cirrhosis

NCT02230670
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 21, 2026, 6:55 PM EDT
Not listed Not applicable Interventional

tDCS and Robotic Training in Adults With Cerebral Palsy

NCT03038269
View directory record Official record
Conditions
Cerebral Palsy, Hemiplegia
Interventions
Upper Extremity Robotics, tDCS
Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
15 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

NCT00041483
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT)
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 21, 2026, 6:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 21, 2026, 6:55 PM EDT